Nachrichten zur Johnson Matthey PLC Aktie

Johnson & Johnson: $2 Billion Buyout Of Antibody Drug Conjugate Specialist Ambrx Is Good Business

…

This Dividend Stock Has a $13 Billion Secret Weapon @themotleyfool #stocks $JNJ

Johnson & Johnson made a key decision last year.…

Johnson & Johnson (JNJ) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

…

Johnson & Johnson to acquire Ambrx Biopharma for $2 billion By Investing.com

Johnson & Johnson to acquire Ambrx Biopharma for $2 billion…

Johnson & Johnson: EPS Growth Returns In 2024, JPM Healthcare Conference On Tap

…

Johnson & Johnson erwirbt das Biotech Unternehmen Ambrx für 2 Milliarden Dollar

…

Johnson & Johnson: Übernahme lässt diese Aktie explodieren

Johnson & Johnson hat einen entscheidenden Schritt zur Erweiterung seines Onkologie-Portfolios unternommen, indem das Unternehmen die Absicht zur Akquisition eines…

Johnson & Johnson schlägt zu – 100 Prozent Aufschlag

Johnson & Johnson (J&J) wird 2,0 Milliarden Dollar in bar zahlen, um Ambrx Biopharma zu erwerben und damit einen Entwickler…

PRTG: Bridging I-O: Working in Harmony with Checkpoints

By John Vandermosten, CFA NASDAQ:PRTG READ THE FULL PRTG RESEARCH REPORT We are initiating coverage of Portage Biotech Inc. (NASDAQ:PRTG) with a target…

Johnson & Johnson: 2,0 Milliarden Dollar für Ambrx Biopharma - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von "Der Aktionär": Michael Diertl vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die…

Johnson & Johnson: Übernahme lässt diese Aktie explodieren

Johnson & Johnson plant die Übernahme eines Biotechnologieunternehmens für zwei Milliarden US-Dollar, um sein Onkologie-Portfolio zu erweitern.…

Johnson & Johnson to acquire Ambrx for $2B

Johnson & Johnson (NYSE:JNJ) has announced its definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company, in an all-cash...…

Johnson & Johnson to acquire Ambrx in $2 billion deal

…

Johnson & Johnson to Acquire Ambrx for $2 billion By Investing.com

Johnson & Johnson to Acquire Ambrx for $2 billion…

Johnson & Johnson: Kursziel gekürzt

London (www.aktiencheck.de) - Rating-Update: Die Analysten von Barclays stufen die Aktie von Johnson & Johnson (J&J) (ISIN: US4781601046, WKN: 853260, Ticker-Symbol:…

Johnson & Johnson: Overblown Stelara Concerns Distract From Value

…

Johnson & Johnson: A Defensive Dividend King Set To Outperform The S&P 500

…

Johnson & Johnson: One Of The Worlds Safest Stocks Could Return +10% Per Year

…

Johnson & Johnson: Rock Solid 3% Yield With Over 10% Annual Return Potential (Rating Upgrade)

…

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what…

Judge certifies Johnson & Johnson shareholder class action over talc disclosures By Reuters

© Reuters. FILE PHOTO: Bottles of Johnson & Johnson baby powder line a drugstore shelf in New York October 15,…

Johnson & Johnson holders allowed to sue as a class over talc disclosures, judge rules

…

Judge certifies Johnson & Johnson shareholder class action over talc disclosures By Reuters

Judge certifies Johnson & Johnson shareholder class action over talc disclosures…

Johnson & Johnson: Ottava Surgical Robot Is A Growth Tailwind

…

Johnson & Johnson: Neues Kursziel

New York (www.aktiencheck.de) - Rating-Update: Terence Flynn, Analyst von Morgan Stanley, bewertet die Aktie von Johnson & Johnson (J&J) (ISIN: US4781601046,…

Disposable Surgical Sheet Market Latest Report | Expansive Coverage on the Profit Sources

Companies covered in this report are Cardinal Health, Paul Hartmann AG, Standard Textile Co., Medline Industries Inc., Molnlycke Health Care…

Johnson & Johnson: Herabstufung! Gewinnwachstum gedämpft - Aktienanalyse

San Francisco (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Wells Fargo Advisors: Larry Biegelsen, Analyst von Wells Fargo Advisors, stuft die Aktie…

Per-Encounter Medical Market is Booming and Expected to Reach USD 377.93 Billion by 2031 | Latest InsightAce Study

Companies covered in this study are Abbott, Cardinal Health, Johnson & Johnson, Medtronic, 3M, Steris, Catalent Inc., Smiths Medical Inc.,…

A CEO contender left Johnson & Johnson. Was she penalized for saying she wanted to be a CEO?

…

Johnson & Johnson legt Enterprise Business Review vor - Aktienanalyse

Toronto (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von RBC Capital Markets: Die Analysten vom Investmenthaus RBC Capital Markets stufen die Aktie von…

Johnson & Johnson says its finally making progress on disturbing cancer lawsuits

J&J is facing tens of thousands of cases involving its talc-based powder.…

Johnson & Johnson: Kursziel nach Enterprise Business Review erhöht - Aktienanalyse

St. Louis (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Stifel: Rick Wise, Analyst von Stifel, erhöht in einer aktuellen Aktienanalyse sein Kursziel…

Baby Care Products Market Size to Surpass USD 331.92 Billion by 2029 | Exhibiting a CAGR of 6.40%

Key companies covered in baby care products market are Honasa Consumer Private Limited (Mamaearth) (India), Beiersdorf AG (Germany), Sebapharma GmbH…

Pharma Stocks With Nice Dividends: The RX Investors Need

Healthcare stocks like AbbVie and Johnson & Johnson are cash rich and offer solid dividend growth.…

The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile US, Caterpillar, Broadcom and Starbucks

Johnson & Johnson, T-Mobile US, Caterpillar, Broadcom and Starbucks are included in this Analyst Blog.…

NYSE-Wert J&J-Aktie schwächelt: Johnson & Johnson rechnet 2024 mit abnehmender Umsatzdynamik - Konkurrenz wächst

Das Management rechnet für 2024 lediglich damit, aus eigener Kraft, und abseits des Beitrags durch die COVID-Impfung, den Erlös um…

J&J forecasts 2024 sales growth of up to 6%

Johnson & Johnson (NYSE:JNJ) said Tuesday that it expects its 2024 operation sales growth to grow between 5% and 6%…

WDH/Nachahmerkonkurrenz: Johnson & Johnson rechnet mit weniger Wachstum

(Tippfehler in der Überschrift behoben) NEW BRUNSWICK (dpa-AFX) - Wegen zunehmender Generika-Konkurrenz für einen seiner…

Nahmahmerkonkurrenz: Johnson & Johnson rechnet mit weniger Wachstum

NEW BRUNSWICK (dpa-AFX) - Wegen zunehmender Generika-Konkurrenz für einen seiner wichtigsten Kassenschlager rechnet der Arzneimittelhersteller Johnson & Johnson mit…

Nahmahmerkonkurrenz: Johnson & Johnson rechnet mit weniger Wachstum

NEW BRUNSWICK (dpa-AFX) - Wegen zunehmender Generika-Konkurrenz für einen seiner wichtigsten Kassenschlager rechnet der Arzneimittelhersteller Johnson & Johnson mit einer…

Johnson & Johnson forecasts as much as 6% sales growth in 2024

Johnson & Johnson on Tuesday forecast revenue growth of 5% to 6% for the next year, as it banks on…

Johnson & Johnson sets 2024 guidance impacted from Laminar buyout

…

Johnson & Johnson forecasts as much as 6% sales growth in 2024

Johnson & Johnson on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand…

Johnson & Johnson forecasts as much as 6% sales growth in 2024

…

Johnson & Johnson forecasts as much as 6% sales growth in 2024 By Reuters

Johnson & Johnson forecasts as much as 6% sales growth in 2024…

Multiple Myeloma Market revenue to surpass USD 71 Billion by 2035, says Research Nester

Major multiple myeloma market players include Amgen Inc., Johnson & Johnson, Takeda Pharmaceuticals Company Limited, Novartis AG, Sanofi, Teva Pharmaceuticals…

Buffett Just Sold Dividend Kings Johnson & Johnson And Procter & Gamble - Buy This One Instead

…

Stocks To Watch: Big Week On Tap For McDonalds, Shopify, GameStop, And Johnson & Johnson

…

Johnson & Johnson transition underway, UBS assesses upcoming analyst day By Investing.com

Johnson & Johnson transition underway, UBS assesses upcoming analyst day…

Here are Fridays biggest analyst calls: Tesla, Boeing, Amazon, Delta, Spotify, Alibaba, Johnson & Johnson & more

Here are the biggest calls on Wall Street on Friday.…